ArticleScientific reports2025
Structural and diffusion imaging in olfactory-related brain regions in Parkinson's disease: predictors of clinical progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory dysfunction is a prevalent non-motor symptom in Parkinson's disease (PD). Structural and diffusion MRI studies suggest that olfactory-related brain regions undergo significant neurodegenerative changes in PD. The current study aims to explore the longitudinal structural and diffusion imaging in olfactory-related regions in PD over four years. The relationships between baseline imaging and fluid biomarkers, and subsequent cognitive and clinical changes were also explored. We analyzed 97 newly diagnosed early-stage PD patients from the Parkinson's Progression Markers Initiative (PPMI) who underwent T1-weighted MRI, diffusion tensor imaging (DTI), and clinical assessments at baseline, two years, and four years. Structural and diffusion measures of olfactory-related regions were extracted using FreeSurfer and ExploreDTI. Baseline fluid biomarkers were also evaluated. Baseline mean diffusivity (MD) displayed significant associations with further cognitive changes across multiple regions, including amygdala, orbitofrontal cortex (OFC), insula, and thalamus (β=-0.214 to - 0.422). Baseline structural measures, including amygdala volume and entorhinal and OFC thickness, were associated with subsequent changes in cognitive and Unified Parkinson's Disease Rating Scale (UPDRS) scores (β = 0.264 to 0.402). Moreover, baseline serum neurofilament-light chain levels predicted multiple cognitive score changes (β= - 0.603 to - 0.331). Longitudinal analyses revealed a significant MD increase in the thalamus along with gradual reductions in volume and cortical thickness in the amygdala, insula, OFC, and entorhinal cortex (FDR-adjusted p < 0.05). Linear mixed-effect models further confirmed thalamic diffusion metrics as a predictor of cognitive deterioration. Olfactory-related regions exhibit progressive neurodegeneration in early PD, contributing to worsening cognition and disease severity. Baseline imaging and fluid biomarkers may serve as prognostic tools in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.